Edgewise Therapeutics/$EWTX
1D1W1MYTD1Y5YMAX
Capital at risk
About Edgewise Therapeutics
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
- Ticker
- $EWTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 127
- Headquarters
- Boulder, United States
- Website
- edgewisetx.com
EWTX Metrics
BasicAdvanced
$4.5B
-
-$1.85
0.32
-
Price and volume
Market cap
$4.5B
Beta
0.32
52-week high
$48.51
52-week low
$14.25
Average daily volume
1.5M
Financial strength
Current ratio
16.236
Quick ratio
15.864
Long term debt to equity
0.006
Total debt to equity
0.008
Profitability
EBITDA (TTM)
-216.769
Management effectiveness
Return on assets (TTM)
-25.03%
Return on equity (TTM)
-38.03%
Valuation
Price to book
9.96
Price to tangible book (TTM)
9.96
Price to free cash flow (TTM)
-27.784
Free cash flow yield (TTM)
-3.60%
Free cash flow per share (TTM)
-1.49
Growth
Earnings per share change (TTM)
19.30%
3-year earnings per share growth (CAGR)
11.26%
What the Analysts think about EWTX
Analyst ratings (Buy, Hold, Sell) for Edgewise Therapeutics stock.
Analyst projections of the future price of Edgewise Therapeutics stock.
Bulls say / Bears say
EDG-7500 produced encouraging 12-week Phase 2 results in both obstructive and non-obstructive HCM, including improvements in disease biomarkers and patient-reported symptoms. The company plans to start a Phase 3 trial in the fourth quarter of 2026. (Endpoints News, PR Newswire)
The sale of sevasemten to Servier delivered $1.55 billion upfront, with up to $1.1 billion in further milestones. Edgewise says the proceeds should fund EDG-7500 through potential approval and give it scope to develop its cardiovascular pipeline without near-term financing pressure. (PR Newswire, PR Newswire)
EDG-7500 did not produce meaningful falls in left-ventricular ejection fraction in the Phase 2 study, which analysts said could become a competitive advantage if it avoids the monitoring burden attached to rival HCM medicines. (BioSpace, PR Newswire)
The encouraging EDG-7500 evidence comes from a small, open-label Phase 2 Part D study of 53 patients, not a confirmatory trial. Two new atrial-fibrillation events occurred, and larger trials could produce different safety or efficacy results. (PR Newswire, BioSpace)
By selling sevasemten and the muscular-dystrophy business, Edgewise gave up direct ownership of a late-stage asset and now retains only potential milestone payments. That removes a major source of possible upside if the Becker or Duchenne programmes succeed. (PR Newswire, Servier)
EDG-7500's commercial position is not yet settled: analysts said its non-obstructive HCM data did not clearly outperform Myqorzo. A longer and larger Phase 3 programme will therefore need to prove both clinical benefit and differentiation against established competitors. (BioSpace, Endpoints News)
Data summarised monthly by Lightyear AI. Last updated on 23 Sept 2026.
EWTX Financial Performance
Revenues and expenses
EWTX Earnings Performance
Company profitability
Upcoming events
No upcoming events
EWTX News
AllArticlesVideos
Funds containing EWTX
AllUSDGBPEUR
Fund name | Fund size | $EWTX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.29% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.29% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.10% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.10% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.